Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Our proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. Our targeted nanoparticles are rationally designed to deliver bioactive molecules to specific immune cells in the body. Depending on the cellular target and the molecular information encoded in the payload, the nanoparticles can potently stimulate or modify immune responses.

The cellular and humoral components of the immune system influence nearly all aspects of human health. Their function critically determines the incidence, progression and remission of many major pathologies, including infections, cancer, cardiovascular diseases, metabolic diseases, central nervous system diseases, autoimmunity, allergies, asthma and acute and chronic inflammatory conditions. Selecta's proprietary targeted immunomodulatory nanoparticle platform technology enables direct and specific interaction with the immune system to treat and prevent a wide range of diseases to greatly improve the lives of patients.

Selecta was founded based on complimentary research by three academic pioneers. The advanced particle technology of Professors Robert Langer (MIT) and Omid Farokhzad (Brigham and Women’s Hospital, Harvard Medical School), two leaders in the fields of drug delivery and targeted nanotechnology, have been combined with the insights into the workings of the immune system made by Professor Ulrich von Andrian (Harvard Medical School), a leader in the field of immunology, to enable Selecta’s broad and powerful product platform. Selecta has assembled an outstanding team of management and advisors, all of whom are preeminent in their own respective fields. Selecta's management team has been drawn from successful companies in the areas of polymeric drug delivery, immunology and product platforms, including Alkermes, Coley, AIR, and Sepracor.

Selecta Biosciences was founded in December 2007 and was launched with financing from Flagship Ventures and Polaris Venture Partners. Selecta has licensed a broad patent estate from MIT, Brigham and Women's and Harvard Medical School to commercialize targeted nanoparticle technology for immune modulation.